Genmab A/S ADS (GMAB) Stock: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$32.47
0.24 (0.74%)
â˛
5d:
-5.64%
30d:
+3.34%
90d:
+28.65%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GMAB is fairly priced but lacks strong directional signals. At 6.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GMAB is fairly priced but lacks strong directional signals. At 6.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$52.64
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$32.68
0.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $32.47, which is considered fair relative to its 30-day fair value range of $30.77 to $34.03. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.4) compared to its historical average (17.0). At these levels, the market is pricing in 6.3% annual earnings growth.
Technical Outlook: Technically, GMAB is in a strong uptrend. The price is currently testing key support at $32.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GMAB scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $38.84 (+19.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMAB is in a strong uptrend. The price is currently testing key support at $32.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GMAB scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $38.84 (+19.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$30.77 -
$34.03
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($38.84)
- BULLISH: Expecting earnings turnaround to 6.3% growth with 24.9% revenue growth
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$30.77 -
$34.03
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$32.21
Resistance Level
$34.66
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.42
Wall Street Target
$38.84
(+19.6%)
Revenue Growth (YoY)
24.9%
Earnings Growth (YoY)
-9.4%
Profit Margin
19.1%
Valuation Premium vs History
+6.3% premium
PE vs Historical
20.4 vs 17.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.3%
(market-implied from PE analysis)
1-Year Target
$34.52
(+6%)
2-Year Target
$36.69
(+13%)
3-Year Target
$39.00
(+20%)
3-Yr Target (if PE normalizes)
(PE: 20â17)
PE COMPRESSION
$32.47
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 40.7%)
$90.46
(+179%)
Base:
(SPY PE: 20.2, Growth: 40.7%)
$89.34
(+175%)
Bear:
(PE: 17.0, Growth: 40.7%)
$75.30
(+132%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 26.20 | Current EPS (TTM): $1.23
Bull Case
$45.83
(+41%)
Analyst growth 29.3%, PE expands to 28.8
Base Case
$41.66
(+28%)
Market implied 29.3%, PE stable at 26.2
Bear Case
$21.92
(-33%)
Severe decline -20.0%, PE contracts to 22.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 13, 2026 9:40 PM ET
Data refreshes hourly during market hours. Next update: 10:40 PM
Data refreshes hourly during market hours. Next update: 10:40 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
